MedTrace Logo

ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial

NCT00161070 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4500

Last updated 2007-03-22

No results posted yet for this study

Summary

The objective of ESPRIT was to compare the efficacy and safety of mild anticoagulation or a combination treatment of aspirin and dipyridamole with the efficacy and safety of treatment with aspirin alone after cerebral ischemia of arterial origin.

Conditions

  • Brain Ischemia
  • Transient Ischemic Attack
  • Arteriosclerosis

Interventions

DRUG

anticoagulation

DRUG

aspirin and dipyridamole

DRUG

aspirin alone

Sponsors & Collaborators

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • A. Algra, Professor · UMC Utrecht

  • J. Gijn Van, Professor · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-07-31
Completion
2006-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161070 on ClinicalTrials.gov